Rheumatoid Arthritis Test Predicts Patient Response to Drugs
By LabMedica International staff writers Posted on 25 Nov 2015 |
Image: The Vectra DA disease activity test measures and scores 12 serum proteins associated with rheumatoid arthritis (RA) (Photo courtesy of Crescendo Bioscience).
A diagnostic for measuring the severity of rheumatoid arthritis can help guide patient selection for biologic or non-biologic drugs by predicting their response to the various therapies and treatment strategies.
The multi-biomarker blood test for rheumatoid arthritis disease (RA) activity integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions.
A recent study from scientists at Helsingborg Hospital (Sweden) evaluated whether the Vectra DA score could be used to predict the optimal choice of second-line treatment for 157 patients with RA who were incomplete responders to the immunosuppressant methotrexate (MTX). The findings demonstrated that, in patients with early RA and incomplete response to MTX, the Vectra DA test predicted the relative efficacy of second-line treatment with triple therapy versus anti-TNF. A Vectra DA score above 44 being indicative of high disease activity.
Vectra DA is manufactured by Crescendo Bioscience (South San Francisco, CA, USA). Two other studies presented provide guidance to physicians about discontinuation of therapy. One found that patients with a high Vectra DA score and positive results on a single-biomarker test had relapse rate of 76%, compared to 32% among those with a low Vectra DA score. A third study found that high Vectra DA scores were correlated with relapse of the disease in patients tapering their drug therapies. Vectra DA can help identify patients who show clinical improvement, but continue to have high levels of underlying disease activity, making them vulnerable to relapses or flares.
Elena Hitraya, MD, PhD, Chief Medical Officer at Crescendo, said, “The immunosuppressant methotrexate is the first-line therapy for rheumatoid arthritis, but it isn't always effective. At this point physicians need to make a choice. The options that they have is adding a synthetic biological drug, or adding a biological drug, which is most often anti-tumor necrosis factor (TNF).” The studies were presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held November 7–11, 2015, in San Francisco (CA, USA).
Related Links:
Helsingborg Hospital
Crescendo Bioscience
The multi-biomarker blood test for rheumatoid arthritis disease (RA) activity integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions.
A recent study from scientists at Helsingborg Hospital (Sweden) evaluated whether the Vectra DA score could be used to predict the optimal choice of second-line treatment for 157 patients with RA who were incomplete responders to the immunosuppressant methotrexate (MTX). The findings demonstrated that, in patients with early RA and incomplete response to MTX, the Vectra DA test predicted the relative efficacy of second-line treatment with triple therapy versus anti-TNF. A Vectra DA score above 44 being indicative of high disease activity.
Vectra DA is manufactured by Crescendo Bioscience (South San Francisco, CA, USA). Two other studies presented provide guidance to physicians about discontinuation of therapy. One found that patients with a high Vectra DA score and positive results on a single-biomarker test had relapse rate of 76%, compared to 32% among those with a low Vectra DA score. A third study found that high Vectra DA scores were correlated with relapse of the disease in patients tapering their drug therapies. Vectra DA can help identify patients who show clinical improvement, but continue to have high levels of underlying disease activity, making them vulnerable to relapses or flares.
Elena Hitraya, MD, PhD, Chief Medical Officer at Crescendo, said, “The immunosuppressant methotrexate is the first-line therapy for rheumatoid arthritis, but it isn't always effective. At this point physicians need to make a choice. The options that they have is adding a synthetic biological drug, or adding a biological drug, which is most often anti-tumor necrosis factor (TNF).” The studies were presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held November 7–11, 2015, in San Francisco (CA, USA).
Related Links:
Helsingborg Hospital
Crescendo Bioscience
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines